ClinicalTrials.gg
RecruitingNCT07617376Updated Jun 1, 2026

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

A Phase 4 interventional study of Influenza vaccination in Myocardial Infarction, Decompensated Chronic Heart Failure and Acute Heart Failure (AHF), sponsored by Wroclaw Medical University. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Wroclaw Medical University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2025, registered May 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Poland.

Planned enrollment
47th of 77
400 · median 1,012
Started
2025
with 4 others
Phase 4
13 of 89
4 open now
Primary completion
2026-12
later than 3 of 19 live
Registered
87th of 89
by date
Lead sponsor
3 of 89
Wroclaw Medical University

Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 47th largest by planned enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2025, is one of 13 in phase 4, reaches primary completion later than 3 of the 19 other live ones, and was the 87th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Myocardial Infarction with a site in Poland, or all of them as a file.
02

Study summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.

In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

03

Conditions studied

  • Myocardial Infarction
  • Decompensated Chronic Heart Failure
  • Acute Heart Failure (AHF)
  • Pulmonary Embolism Acute
  • Hypertension Emergency
  • Arrhythmias

Keywords

  • influenza vaccination
  • acute cardiac emergencies
  • pre-discharg vaccination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute cardiac hospitalization,
  • Planned discharge home within the next 48 hours following completion of in-hospital treatment,
  • No prior influenza vaccination for the current influenza season.

Exclusion criteria

Exclusion Criteria:

  • History of a severe adverse reaction to influenza vaccination,
  • Allergy to any component of the vaccine to be administered,
  • Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,
  • Antibiotic therapy to be continued after discharge.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • No intervention
    Standard of care

    standard of care (SOC), including recommendation for influenza vaccination in primary care

  • Experimental
    Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions

    pre-discharge influenza vaccine administration

    Biological: Influenza vaccination

Interventions

  • BiologicalInfluenza vaccination

    Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions

06

What researchers measure

Primary outcomes

  1. infection, unplanned cardiovascular hospitalization or cardiovascular death

    For the purposes of the study, infection was defined as an acute illness characterized by at least one of the following symptoms or events: * typical symptoms (malaise, fatigue, etc.), * self-measured body temperature of 38°C or higher, * the need for antipyretic / analgesic medication, * medical consultation (e.g. with general practitioner) due to infection, * unplanned hospitalization due to infection.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 13 months is below that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 1, 2026
StartActual
Nov 12, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 1, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617376
Lead sponsor
Wroclaw Medical University
Responsible party
Michał Tkaczyszyn, MD (Dr, Wroclaw Medical University) — Principal investigator
First posted
Jun 1, 2026
Start date
Nov 12, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Piotr Kübler Kübler, Professor
Contact
piotr.kubler@umw.edu.pl
48717364240
Michal Tkaczyszyn, M.D., PhD
Contact
michal.tkaczyszyn@umw.edu.pl
48 71 733 11 12
Jan Biegus, Professor
study chair · Wroclaw Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion